-
Something wrong with this record ?
Biocompatible glyconanomaterials based on HPMA-copolymer for specific targeting of galectin-3
P. Bojarová, MR. Tavares, D. Laaf, L. Bumba, L. Petrásková, R. Konefał, M. Bláhová, H. Pelantová, L. Elling, T. Etrych, P. Chytil, V. Křen,
Language English Country England, Great Britain
Document type Journal Article
NLK
BioMedCentral
from 2003-12-01
BioMedCentral Open Access
from 2003
Directory of Open Access Journals
from 2003
Free Medical Journals
from 2003
PubMed Central
from 2003
Europe PubMed Central
from 2003
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2003-01-01
Open Access Digital Library
from 2003-01-01
Medline Complete (EBSCOhost)
from 2003-01-28
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2003
Springer Nature OA/Free Journals
from 2003-12-01
- MeSH
- Acrylamides chemistry metabolism MeSH
- Galectin 3 metabolism MeSH
- Glycoconjugates chemistry metabolism MeSH
- Drug Delivery Systems * MeSH
- Humans MeSH
- Nanostructures chemistry MeSH
- Drug Carriers chemistry metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Galectin-3 (Gal-3) is a promising target in cancer therapy with a high therapeutic potential due to its abundant localization within the tumor tissue and its involvement in tumor development and proliferation. Potential clinical application of Gal-3-targeted inhibitors is often complicated by their insufficient selectivity or low biocompatibility. Nanomaterials based on N-(2-hydroxypropyl)methacrylamide (HPMA) nanocarrier are attractive for in vivo application due to their good water solubility and lack of toxicity and immunogenicity. Their conjugation with tailored carbohydrate ligands can yield specific glyconanomaterials applicable for targeting biomedicinally relevant lectins like Gal-3. RESULTS: In the present study we describe the synthesis and the structure-affinity relationship study of novel Gal-3-targeted glyconanomaterials, based on hydrophilic HPMA nanocarriers. HPMA nanocarriers decorated with varying amounts of Gal-3 specific epitope GalNAcβ1,4GlcNAc (LacdiNAc) were analyzed in a competitive ELISA-type assay and their binding kinetics was described by surface plasmon resonance. We showed the impact of various linker types and epitope distribution on the binding affinity to Gal-3. The synthesis of specific functionalized LacdiNAc epitopes was accomplished under the catalysis by mutant β-N-acetylhexosaminidases. The glycans were conjugated to statistic HPMA copolymer precursors through diverse linkers in a defined pattern and density using Cu(I)-catalyzed azide-alkyne cycloaddition. The resulting water-soluble and structurally flexible synthetic glyconanomaterials exhibited affinity to Gal-3 in low μM range. CONCLUSIONS: The results of this study reveal the relation between the linker structure, glycan distribution and the affinity of the glycopolymer nanomaterial to Gal-3. They pave the way to specific biomedicinal glyconanomaterials that target Gal-3 as a therapeutic goal in cancerogenesis and other disorders.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000359
- 003
- CZ-PrNML
- 005
- 20190111150246.0
- 007
- ta
- 008
- 190107s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12951-018-0399-1 $2 doi
- 035 __
- $a (PubMed)30236114
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bojarová, P $u Institute of Microbiology, Czech Academy of Sciences, Vídeňská 1083, 14220, Prague 4, Czech Republic. bojarova@biomed.cas.cz.
- 245 10
- $a Biocompatible glyconanomaterials based on HPMA-copolymer for specific targeting of galectin-3 / $c P. Bojarová, MR. Tavares, D. Laaf, L. Bumba, L. Petrásková, R. Konefał, M. Bláhová, H. Pelantová, L. Elling, T. Etrych, P. Chytil, V. Křen,
- 520 9_
- $a BACKGROUND: Galectin-3 (Gal-3) is a promising target in cancer therapy with a high therapeutic potential due to its abundant localization within the tumor tissue and its involvement in tumor development and proliferation. Potential clinical application of Gal-3-targeted inhibitors is often complicated by their insufficient selectivity or low biocompatibility. Nanomaterials based on N-(2-hydroxypropyl)methacrylamide (HPMA) nanocarrier are attractive for in vivo application due to their good water solubility and lack of toxicity and immunogenicity. Their conjugation with tailored carbohydrate ligands can yield specific glyconanomaterials applicable for targeting biomedicinally relevant lectins like Gal-3. RESULTS: In the present study we describe the synthesis and the structure-affinity relationship study of novel Gal-3-targeted glyconanomaterials, based on hydrophilic HPMA nanocarriers. HPMA nanocarriers decorated with varying amounts of Gal-3 specific epitope GalNAcβ1,4GlcNAc (LacdiNAc) were analyzed in a competitive ELISA-type assay and their binding kinetics was described by surface plasmon resonance. We showed the impact of various linker types and epitope distribution on the binding affinity to Gal-3. The synthesis of specific functionalized LacdiNAc epitopes was accomplished under the catalysis by mutant β-N-acetylhexosaminidases. The glycans were conjugated to statistic HPMA copolymer precursors through diverse linkers in a defined pattern and density using Cu(I)-catalyzed azide-alkyne cycloaddition. The resulting water-soluble and structurally flexible synthetic glyconanomaterials exhibited affinity to Gal-3 in low μM range. CONCLUSIONS: The results of this study reveal the relation between the linker structure, glycan distribution and the affinity of the glycopolymer nanomaterial to Gal-3. They pave the way to specific biomedicinal glyconanomaterials that target Gal-3 as a therapeutic goal in cancerogenesis and other disorders.
- 650 _2
- $a akrylamidy $x chemie $x metabolismus $7 D000178
- 650 _2
- $a nosiče léků $x chemie $x metabolismus $7 D004337
- 650 12
- $a lékové transportní systémy $7 D016503
- 650 _2
- $a galektin 3 $x metabolismus $7 D037502
- 650 _2
- $a glykokonjugáty $x chemie $x metabolismus $7 D006001
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nanostruktury $x chemie $7 D049329
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Tavares, M R $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovský Sq. 2, 16206, Prague 6, Czech Republic.
- 700 1_
- $a Laaf, D $u Laboratory for Biomaterials, Institute for Biotechnology and Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University, Pauwelsstraße 20, 52074, Aachen, Germany.
- 700 1_
- $a Bumba, L $u Institute of Microbiology, Czech Academy of Sciences, Vídeňská 1083, 14220, Prague 4, Czech Republic.
- 700 1_
- $a Petrásková, L $u Institute of Microbiology, Czech Academy of Sciences, Vídeňská 1083, 14220, Prague 4, Czech Republic.
- 700 1_
- $a Konefał, R $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovský Sq. 2, 16206, Prague 6, Czech Republic.
- 700 1_
- $a Bláhová, M $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovský Sq. 2, 16206, Prague 6, Czech Republic.
- 700 1_
- $a Pelantová, H $u Institute of Microbiology, Czech Academy of Sciences, Vídeňská 1083, 14220, Prague 4, Czech Republic.
- 700 1_
- $a Elling, L $u Laboratory for Biomaterials, Institute for Biotechnology and Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University, Pauwelsstraße 20, 52074, Aachen, Germany.
- 700 1_
- $a Etrych, T $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovský Sq. 2, 16206, Prague 6, Czech Republic.
- 700 1_
- $a Chytil, P $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovský Sq. 2, 16206, Prague 6, Czech Republic. chytil@imc.cas.cz.
- 700 1_
- $a Křen, V $u Institute of Microbiology, Czech Academy of Sciences, Vídeňská 1083, 14220, Prague 4, Czech Republic.
- 773 0_
- $w MED00008237 $t Journal of nanobiotechnology $x 1477-3155 $g Roč. 16, č. 1 (2018), s. 73
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30236114 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190111150451 $b ABA008
- 999 __
- $a ok $b bmc $g 1364465 $s 1038482
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 16 $c 1 $d 73 $e 20180920 $i 1477-3155 $m Journal of nanobiotechnology $n J Nanobiotechnology $x MED00008237
- LZP __
- $a Pubmed-20190107